Updated EAS consensus statement on homozygous familial hypercholesterolemia


News - May 16, 2023

The European Atherosclerosis Society (EAS) published a consensus statement on homozygous familial hypercholesterolemia (HoFH) in the European Heart Journal [1], updating the previous statement from 2014.

Since the previous statement, progress has been made in the understanding of the genetic complexity of HoFH and new treatments have been developed. However, persistent questions in HoFH care remain present. Last year, a retrospective cohort study of 751 patients with HoFH from 38 countries demonstrated that underdiagnosis and undertreatment of HoFH remains a current problem in HoFH care [2]. The updated EAS statement provides clinical guidance for early diagnosis, better care, and improved cardiovascular health for patients with HoFH worldwide.


1. Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;ehad197. Online ahead of print.

2. Tromp TR, Hartgers ML, Hovingh GK, et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet. 2022;399(10326):719-728.

Find the 2023 EAS consensus statement at Eur Heart J.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free